Metabolomics as a tool for cardiac research

Griffin, Julian L.; Atherton, Helen; Shockcor, John P.; Atzori, Luigi

doi:10.1038/nrcardio.2011.138

Cited by 232 publications

(190 citation statements)

References 103 publications

(102 reference statements)

Supporting

Mentioning

183

Contrasting

Unclassified

Order By: Relevance

“…Only one sample from the control set and one from the group of multiple myeloma patients at the time of diagnosis were identified as strong outliers on their group, outside the Hotellings 95% confidence limit. They displayed a metabolic profile that has been previously reported to be related to hypertensive patients (17,18), characterized by changes in signals attributed to lipids and lipoproteins, as well as the choline-containing region. Furthermore, the detailed revision of the clinical history of the multiple myeloma patient at the time of diagnosis revealed that the patient was diabetic and hypertensive.…”

Section: Resultsmentioning

confidence: 99%

Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission

Puchades‐Carrasco

Lecumberri

Martínez‐López

et al. 2013

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Multiple myeloma remains an incurable disease. New approaches to develop better tools for improving patient prognostication and monitoring treatment efficacy are very much needed. In this study, we aimed to evaluate the potential of metabolomics by 1 H-NMR to provide information on metabolic profiles that could be useful in the management of multiple myeloma. Experimental Design: Serum samples were collected from multiple myeloma patients at the time of diagnosis and after achieving complete remission. A matched control set of samples was also included in the study. The 1 H-NMR measurements used to obtain the metabolic profile for each patient were followed by the application of univariate and multivariate statistical analyses to determine significant differences.Results: Metabolic profiles of multiple myeloma patients at diagnosis exhibited higher levels of isoleucine, arginine, acetate, phenylalanine, and tyrosine, and decreased levels of 3-hydroxybutyrate, lysine, glutamine, and some lipids compared with the control set. A similar analysis conducted in multiple myeloma patients after achieving complete remission indicated that some of the metabolic changes (i.e., glutamine, cholesterol, lysine) observed at diagnosis displayed a variation in the opposite direction upon responding to treatment, thus contributing to multiple myeloma patients having a closer metabolic profile to those of healthy individuals after the disappearance of major disease manifestations.Conclusions: The results highlight the potential of metabolic profiles obtained by 1 H-NMR in identifying multiple myeloma biomarkers that may be useful to objectively discriminate individuals with and without multiple myeloma, and monitor response to treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission

Puchades‐Carrasco

Lecumberri

Martínez‐López

et al. 2013

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Detailed information regarding NMR theory, its application and typical chemical shift values is available elsewhere (Blümich 2005). The application of NMR spectroscopy in metabolomics ranges from pharmaceutical studies (Lindon et al 2007) to cardiovascular biomarker identification (Griffin et al 2011, Rhee & Gerszten 2012.…”

Section: Nmr Spectroscopymentioning

confidence: 99%

Metabolomics in diabetes research

Friedrich¹

2012

Journal of Endocrinology

124

View full text Add to dashboard Cite

Diabetes represents one of the most important global health problems because it is associated with a large economic burden on the health systems of many countries. Whereas the diagnosis and treatment of manifest diabetes have been well investigated, the identification of novel pathways or early biomarkers indicative of metabolic alterations or insulin resistance related to the development of diabetes is still in progress. Over half of the type 2 diabetes patients show manifestations of diabetes-related diseases, which highlight the need for early screening markers of diabetes. During the last decade, the rapidly growing research field of metabolomics has introduced new insights into the pathology of diabetes as well as methods to predict disease onset and has revealed new biomarkers. Recent epidemiological studies first used metabolism to predict incident diabetes and revealed branched-chain and aromatic amino acids including isoleucine, leucine, valine, tyrosine and phenylalanine as highly significant predictors of future diabetes. This review summarises the current findings of metabolic research regarding diabetes in animal models and human investigations.

show abstract

“…The metabolomic fingerprint, derived from specific protein enzymatic processes, directly correlates with the clinical phenotype of the diseases. [1][2][3] Cardiac resynchronization therapy (CRT) has shown a clear clinical benefit in heart failure patients by improving symptoms, quality of life, exercise capacity and cardiac function, significantly reducing morbidity and mortality, 4-9 but up to 40% of heart failure patients are nonresponder to CRT. 10,11 As an emerging discipline for molecular profiling, metabolomic may increase understanding of human diseases and clinical risk because changes in metabolite levels provide a real-time estimate of disease state and reflect the integrated effects of genomic, transcriptomic and proteomic variation.…”

Section: Introductionmentioning

confidence: 99%